Role of β2-microglobulin and lactoferrin in differential diagnosis of uremic pseudoperitonitis and peritonitis in patients with renal replacement therapy (program hemodialysis)

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The significance of the serum concentrations of β2-microglobulin and lactoferrin of the patients on a renal replacement therapy (program hemodialysis) for differential diagnosis of uremic pseudoperitonitis and peritonitis is considered. The study included 56 patients with a suspected peritonitis, admitted urgently to the hospital, who received renal replacement therapy (programmed hemodialysis) in the history. The control group included 50 outpatients on a programmed hemodialysis. The study did not include patients with suspected peritonitis who did not receive programmed hemodialysis in the history. Serum concentrations of β2-microglobulin and lactoferrin were determined in the test groups. Serum β2-microglobulin concentration was found to be statistically higher than the normal in all the patients receiving a history of program hemodialysis procedures. The highest statistically significant concentration of β2-microglobulin was detected in patients with the suspected uremic pseudoperitonitis, both compared to the control group and the group of the patients with diagnosed peritonitis. The highest statistically significant concentration of lactoferrin was detected in patients with the suspected peritonitis receiving a history of program hemodialysis procedures, which is significantly higher both compared to the control group and the patients with a suspected uremic pseudoperitonitis. In the control group of outpatient patients receiving program hemodialysis procedures, no statistically significant differences in serum concentrations of β2-microglobulin and lactoferrin were detected. A statistically significant increase in the concentration of β2-microglobulin was found in uremic pseudoperitonitis, and lactoferrin in peritonitis. The obtained data do not exclude the possibility of using β2-microglobulin to diagnose the uremic pseudoperitonitis, and lactoferrin with a high probability makes it possible to establish the fact of peritonitis.

Full Text

Restricted Access

About the authors

Viktor A. Zurnadzh’yantc

Astrakhan State Medical University

Author for correspondence.
Email: zurviktor@yandex.ru
ORCID iD: 0000-0002-1962-4636
SPIN-code: 4746-5267

doctor of medical sciences, professor

Russian Federation, Astrakhan

Eldar A. Kchibekov

Astrakhan State Medical University

Email: Eidar_76@inbox.ru
ORCID iD: 0000-0001-9213-9541

doctor of medical sciences

Russian Federation, Astrakhan

Kazim G. Gasanov

Astrakhan State Medical University

Email: nazim.gasanov.1985@mail.ru
ORCID iD: 0000-0002-4303-3764
SPIN-code: 1668-9875

post-graduate student

Russian Federation, Astrakhan

References

  1. Smirnov AV, Shilov VA, Dobronravov VF. National recommendations. Chronic kidney disease: basic principles of screening, diagnosis, prevention and treatment approaches. Nephrology. 2012;16(1):1–4. (In Russ.).
  2. Tomilina NA, Andrusev AM, Peregudova NG, et al. Replacement therapy of end-stage chronic renal failure in the Russian Federation in 2010–2015. Report on the data of the All-Russian Register of Renal Replacement Therapy of the Russian Dialysis Society. Nephrology and Dialysis. 2018;19(4):1–95. (In Russ.). doi: 10.28996/1680-4422-2017-4suppl-1-95
  3. Kryukov EV, Potekhin NP, Chaplyuk AL, et. al. Expert approaches to chronic kidney disease. Military Medical Journal. 2016;337(10): 13–18. (In Russ.).
  4. Bikbov BT, Tomilina NA. Composition of patients and indicators of the quality of treatment on replacement therapy for end-stage chronic renal failure in the Russian Federation in 1998–2013. Report on the data of the register of renal replacement therapy of the Russian Dialysis Society. Nephrology and Dialysis. 2016;18(2):123–127. (In Russ.).
  5. Smirnov AV, Dobronravov VA, Kayukov IG, et.al. Chronic kidney disease: Further development of the concept and classification. Nephrology. 2007;11(4):7–15. (In Russ.).
  6. Eilers H, Liu КD, Gruber А, Niemann U. Chronic kidney disease: implications for the perioperative period. Minerva Anestesiol. 2010;76(9):725–736.
  7. Malkov IS, Shaimardanov RSh, Zainutdinov AM. Methodological aspects of laparoscopic sanation in case of diffuse peritonitis. West Surgery. 2003;162(2):28–31. (In Russ.).
  8. Magnuson TH, Bender JS. Cholecystectomy in the peritoneal dialysis patient. Unique advantages to the laparoscopic approach. Surg Endosc Aug. 1995;9(8):908–909. doi: 10.1007/BF00768890
  9. Ryabov SI. The present-day approaches to hemodialysis treatment of patient with chronic renal failure. Nephrology. 1999;3(1): 8–13. (In Russ.). doi: 10.24884/1561-6274-1999-3-1-8-13
  10. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. National Library of Medicine. 2017;389(10075):1238–1252. doi: 10.1016/S0140-6736(16)32064-5
  11. Vatazin AV, Losev GYu, Filizhanko VN, et al. Application of minimally invasive surgical interventions in patients with terminal chronic renal failure receiving peritoneal dialysis. Almanac of Clinical Medicine. 2005;8(4):18–25. (In Russ.).
  12. Vatazin AV, Filizhanko VN, Losev GYu, et al. Laparoscopic operations in patients with terminal chronic renal failure receiving peritoneal dialysis. Almanac of Clinical Medicine. 2007;16:46–51. (In Russ.).
  13. Bikbov BT, Tomilina NA. Substitution therapy for patients with chronic renal failure in the Russian Federation in 1998–2011. Nephrology and Dialysis. 2014;16(1):13–29. (In Russ.).
  14. Smirnov AV, Dobronravov VA, Kayukov IG, et al. Chronic kidney disease: Further development of the concept and classification. Nephrology. 2007;11(4):7–15. (In Russ.). doi: 10.24884/1561-6274-2007-11-4-7-17
  15. Abramova EE, Koroleva IЕ, Tov NL, et al. Death risk factors in patients on hemodialysis. Journal of Siberian Medical Sciences. 2015;6:15. (In Russ.).
  16. Zemchenkov AYu, Tomilina NA. “K/DOQI” refers to the origins of chronic renal failure (about the new K/DOQI section on the diagnosis, classification and assessment of the severity of chronic kidney disease. Nephrology and dialysis. 2004;(3):204–220. (In Russ.).
  17. Kolina IB, Stavrovskaya EV, Shilov EM. Dyslipidemia and chronic progressive kidney disease. Ter Arch. 2004;76(9):75–78. (In Russ.).
  18. Levey AS, Coresh J, Balk E. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137–147. doi: 10.7326/0003-4819-139-2-200307150-00013
  19. Kamiya T, Hirako M, Misu N. Impaired gastric motility and its relationship to gastrointestinal symptoms in patients with chronic renal failure. J Gastroenterol. 2005;40(12):1116–1122. doi: 10.1007/s00535-005-1709-6
  20. Matsuo N, Yokoyama K, Maruyama Y, et.al. Clinical impact of a combined therapy of peritoneal dialysis and hemodialysis. Clin Nephrol. 2010;74(3):209–216. doi: 10.5414/cnp74209
  21. Nazarenko GI, Kishkun AA. Clinical assessment of laboratory research results. Moscow: Medicine; 2000. 544 p. (In Russ.).
  22. Savelyev VS, Gelfand BR, Filimonov MI. Peritonitis. Moscow: Litterra; 2006. 208 p. (In Russ.).
  23. Deegens J, Wetzels J. Fractional excretion of high- and low-molecular weight proteins and outcome in primary focal segmental glomerulosclerosis. Clin Nephrol. 2007;68(4):201–208. doi: 10.5414/cnp68201
  24. Jaques DA, Davenport A. Serum β2-microglobulin as a predictor of residual kidney function in peritoneal dialysis patients. J Nephrol. 2021;34(2):473–481. doi: 10.1007/s40620-020-00906-x
  25. Lutseva OA, Zurnadzhiantc VA, Kchibekov EA, et al. Possibilities of serum indicator enzymes in the differential diagnosis of atypical forms of acute appendicitis. Bulletin of Surgical Ggastroenterology. 2018;(1):54–55. (In Russ.).
  26. Coca S, Parikh C. Urinary Biomarkers for Acute Kidney Injury: Perspectiveson Translation. Clin J Am Soc Nephrol. 2008;3(2): 481–490. doi: 10.2215/cjn.03520807

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Zurnadzh’yantс V.A., Kchibekov E.A., Gasanov K.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 77762 от 10.02.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies